Literature DB >> 11722878

Osteoprotegerin: a new therapeutic agent for the treatment of bone disease.

Eva Grimaud1, Françoise Redini, Dominique Heymann.   

Abstract

Entities:  

Year:  2001        PMID： 11722878     DOI： 10.1016/s1359-6446(01)02037-2

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN： 1359-6446            Impact factor:   7.851


× No keyword cloud information.
  2 in total

1.  Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis.

Authors:  Eva Grimaud; Luc Soubigou; Séverine Couillaud; Patrick Coipeau; Anne Moreau; Norbert Passuti; François Gouin; Françoise Redini; Dominique Heymann
Journal:  Am J Pathol       Date:  2003-11       Impact factor: 4.307

2.  Bone marker gene expression in calvarial bones: different bone microenvironments.

Authors:  Osama Al-Amer
Journal:  J Biol Res (Thessalon)       Date:  2017-05-16       Impact factor: 1.889
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.